| Literature DB >> 30670909 |
Su Young Kim1, Hyun-Soo Kim2, Hong Jun Park1.
Abstract
Colonoscopy is a widely used method for diagnosing and treating colonic disease. The number of colonoscopies is increasing worldwide, and concerns about associated adverse events are growing. Large-scale studies using big data for post-colonoscopy complications have been reported. A colon perforation is a severe complication with a relatively high mortality rate. The perforation rate, as reported in large studies (≥ 50,000 colonoscopies) published since 2000, ranges from 0.005-0.085%. The trend in the overall perforation rate in the past 15 years has not changed significantly. Bleeding is a more common adverse event than perforation. Recent large studies (≥ 50,000 colonoscopies) have reported post-colonoscopy bleeding occurring in 0.001-0.687% of cases. Most studies about adverse events related to colonoscopy were performed in the West, and relatively few studies have been conducted in the East. The incidence of post-colonoscopy complications increases in elderly patients or patients with inflammatory bowel diseases. It is important to use a unified definition and refined data to overcome the limitations of previous studies. In addition, a structured training program for endoscopists and a systematic national management program are needed to reduce post-colonoscopy complications. In this review, we discuss the current trends in colonoscopy related to adverse events, as well as the challenges to be addressed through future research.Entities:
Keywords: Adverse events; Bleeding; Colonoscopy; Perforation; Post-colonoscopy
Mesh:
Year: 2019 PMID: 30670909 PMCID: PMC6337013 DOI: 10.3748/wjg.v25.i2.190
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Summary of calculated incidence rates for perforations related to colonoscopy from recent studies with sample sizes > 50,000 cases n (%)
| Sieg et al[ | 1998-1999 | Prospective study | 2001 | Germany | 82416 | 4 (0.005) |
| Iqbal et al[ | 1994-2000 | Retrospective study | 2005 | United States | 78702 | 72 (0.084) |
| Rabeneck et al[ | 2002-2003 | Population-based cohort study | 2008 | Canada | 97091 | 54 (0.056) |
| Iqbal et al[ | 1980-2006 | Retrospective review | 2008 | United States | 258248 | 180 (0.070) |
| Bokemeyer et al[ | 2003-2006 | Study based on German online registry | 2009 | Germany | 269144 | 55 (0.020) |
| Crispin et al[ | 2006 | Study based on compulsory health insurance (CHI) | 2009 | Germany | 236087 | 69 (0.029) |
| Warren et al[ | 2001-2005 | Population-based, matched cohort study. | 2009 | United States | 53220 | 33 (0.062) |
| Arora et al[ | 1995-2005 | Population-based cohort study | 2009 | United States | 277434 | 228 (0.082) |
| Rabeneck et al[ | 2002-2003 | Population-based cohort study | 2011 | Canada | 67632 | 37 (0.055) |
| Pox et al[ | 2003-2008 | Prospective cross-sectional study | 2012 | Germany | 2821392 | 439 (0.016) |
| Hamdani et al[ | 2002-2010 | Retrospective cross-sectional study | 2013 | United States | 80118 | 50 (0.062) |
| Samalavicius et al[ | 2007-2011 | Retrospective multicenter study | 2013 | Lithuania | 56882 | 40 (0.070) |
| Blotière et al[ | 2010 | Study based on comprehensive French health insurance data (SNIIRAM) | 2014 | France | 947061 | 424 (0.045) |
| Rutter et al[ | 2006-2012 | Study based on English National Health Service Bowel Cancer Screening Program (NHSBCSP) | 2014 | United Kingdom | 130831 | 20 (0.015) |
| Zafar et al[ | 2007-2008 | Health Insurance Portability and Accountability Act compliant study | 2014 | United States | 54039 | 46 (0.085) |
| Bielawska et al[ | 2000-2011 | Prospectively collected data from the Clinical Outcomes Research Initiative (CORI) National Endoscopic Database | 2014 | Canada | 1144900 | 192 (0.017) |
| Shi et al[ | 2000-2012 | Retrospective study | 2014 | China | 110785 | 14 (0.012) |
Figure 1Yearly trends of perforation rates.
Summary of related risk factors for post-polypectomy bleeding[36,41,51,80-84]
| Old age | Polyp size | Cutting mode |
| Anticoagulants | Morphology of polyps | Bowel preparation |
| Cardiovascular disease | Histology | Inadvertent cold polypectomy |
| Chronic vascular disease | Number of resected polyps | Endoscopist’s experience |
| Clopidogrel and concomitant aspirin/nonsteroidal anti-inflammatory drugs | Resection method Use of prophylactic hemostasis |
Summary of calculated incidence rates for bleeding related to colonoscopy from recent studies with sample sizes > 50,000 cases n (%)
| Sieg et al[ | 1998-1999 | Prospective study | 2001 | Germany | 82416 | 1 (0.001) |
| Rabeneck et al[ | 2002-2003 | Population-based cohort study | 2008 | Canada | 97091 | 137 (0.141) |
| Bokemeyer et al[ | 2003-2006 | Study based on German online registry | 2009 | Germany | 269144 | 442 (0.164) |
| Crispin et al[ | 2006 | Study based on compulsory health insurance (CHI) | 2009 | Germany | 236087 | 520 (0.220) |
| Warren et al[ | 2001-2005 | Population-based, matched cohort study | 2009 | United States | 53220 | 340 (0.639) |
| Rabeneck et al[ | 2002-2003 | Population-based cohort study | 2011 | Canada | 67632 | 83 (0.123) |
| Pox et al[ | 2003-2008 | Prospective cross-sectional study | 2012 | Germany | 2821392 | 573 (0.020) |
| Blotière et al[ | 2010 | Study based on comprehensive French health insurance data (SNIIRAM) | 2014 | France | 947061 | 933 (0.099) |
| Rutter et al[ | 2006-2012 | Study based on English National Health Service Bowel Cancer Screening Program (NHSBCSP) | 2014 | United Kingdom | 130831 | 291 (0.222) |
| Zafar et al[ | 2007-2008 | Health Insurance Portability and Accountability Act compliant study | 2014 | United States | 54039 | 371 (0.687) |
Figure 2Yearly trends of bleeding rates.
Perforation rates per colonoscopy indication and procedure type from recent studies with sample sizes > 50,000 cases (%)
| Sieg et al[ | - | - | 0.005 | 0.063 |
| Crispin et al[ | 0.040 | 0.030 | - | - |
| Warren et al[ | 0.056 | 0.050 | 0.052 | 0.070 |
| Arora et al[ | 0.067 | 0.086 | 0.077 | 0.077 |
| Pox et al[ | 0.016 | - | 0.012 | 0.046 |
| Hamdani et al[ | 0.010 | 0.268 | 0.010 | 0.037 |
| Rutter et al[ | 0.063 | - | 0.031 | 0.091 |
| Bielawska et al[ | 0.011 | 0.022 | - | - |
Bleeding rates per colonoscopy indication and procedure type from recent studies with sample sizes > 50,000 cases (%)
| Sieg et al[ | - | - | 0.001 | 0.270 |
| Crispin et al[ | 0.240 | 0.210 | - | - |
| Warren et al[ | 0.206 | 0.375 | 0.336 | 0.874 |
| Pox et al[ | 0.020 | - | 0.001 | 0.092 |
| Rutter et al[ | 0.647 | - | 0.102 | 1.136 |
Summary of major risk factors for perforation and bleeding related to colonoscopy from recent studies with sample sizes > 50,000 cases (%)
| Rabeneck et al[ | Comorbidity score ≥ 3 (OR: 3.73, 95%CI: 1.59-8.77), Polypectomy (OR: 2.96, 95%CI: 2.31-3.80), Old age (OR: 2.06, 95%CI: 1.79-2.37) | Polypectomy (OR: 10.32, 95%CI: 6.52-16.34), Old age (OR: 1.61, 95%CI: 1.20-2.16) |
| Crispin et al[ | Polyp size: 0.5-1 cm (OR: 11.93, 95%CI: 3.02-47.13), Polyp size: 1-3 cm (OR: 28.12, 95%CI: 7.82-101.09), Polyp size > 3 cm (OR: 31.49, 95%CI: 6.37-155.66), Polypectomy (OR: 2.27, 95%CI: 1.39-3.70), Old age (OR: 1.00, 95%CI: 1.00-1.00) | Polyp size: 0.5-1 cm (OR: 5.25, 95%CI: 3.42-8.06), Polyp size: 1-3 cm (OR: 16.84, 95%CI: 11.14-25.46), Polyp size > 3 cm (OR: 27.52, 95%CI: 17.20-44.05), Polypectomy (OR: 60.21, 95%CI: 35.90-100.99), Biopsy (OR: 8.88, 95%CI: 5.06-15.59), Colonoscopy in patients with symptoms (OR: 1.31, 95%CI: 1.04-1.67), Pedunculated polyp (OR: 1.55, 95%CI: 1.26-1.90), Number of polyps: 2-4 (OR: 1.26, 95%CI: 1.06-1.50), Old age (OR: 1.00, 95%CI: 1.00-1.00) |
| Arora et al[ | Colonoscopy indication (obstruction) (OR: 5.09, 95%CI: 3.17-8.20), Colonoscopy procedure | - |
| Pox et al[ | Polypectomy | Polypectomy |
| Hamdani et al[ | Colonoscopy indication: Crohn’s disease (OR: 5.16, 95%CI: 1.79-14.88), Colonoscopy indication: abdominal pain (OR: 5.79, 95%CI: 2.64-12.74), Colonoscopy indication : Diagnostic (OR: 15.33, 95%CI: 7.79-30.18), Inpatient (OR: 11.05, 95%CI: 5.14-23.75), ICU patient (OR: 5.83, 95%CI: 2.80-12.14), Low albumin (≤ 4.0) (OR: 3.58, 95%CI: 1.72-7.47), Old age (OR: 1.03, 95%CI: 1.01-1.05) | - |
| Samalavicius et al[ | Low-volume practice center | - |
| Blotière et al[ | Age: 60-69 (OR: 2.91, 95%CI: 1.66-5.10), Age: 70-79 (OR: 5.38, 95%CI: 3.08-9.40), Age ≥ 80 (OR: 7.51, 95%CI: 4.20-13.45), Emergency colonoscopy (OR: 4.63, 95%CI: 3.52-6.10), Polyp size ≥ 1 cm (OR: 2.72, 95%CI: 2.05-3.60) | Age: 60-69 (OR: 1.70, 95%CI: 1.18-2.43), Age: 70-79 (OR: 2.55, 95%CI: 1.77-3.66), Age ≥ 80 (OR: 3.23, 95%CI: 2.21-4.73), Emergency colonoscopy (OR: 5.99, 95%CI: 5.01-7.15), Polyp size ≥ 1 cm (OR: 5.12, 95%CI: 4.33-6.04), Chronic disease (OR: 1.76, 95%CI: 1.53-2.02), Gender (male) (OR: 1.64, 95%CI: 1.43-1.87) |
| Rutter et al[ | Polypectomy, Location of polyp (cecum) (OR: 5.60, 95%CI: 1.37-22.83) | Polypectomy, Location of polyp (cecum) (OR: 13.50, 95%CI: 3.93-46.42), Increasing polyp size (OR: 4.92, 95%CI: 2.84-8.51) |
| Bielawska et al[ | Age: 60-74 (OR: 2.69, 95%CI: 1.83–3.98), Age ≥ 75 (OR: 5.63, 95%CI: 3.73-8.49), Gender (female) (OR: 2.00, 95%CI: 1.43-2.80), ASA class III (OR: 2.14, 95%CI: 1.22-3.75), ASA class IV/V (OR: 7.20, 95%CI: 2.41-21.50), Hospital setting: university (OR: 2.83, 95%CI: 1.85-4.31), Hospital setting: VA/military (OR: 3.74, 95%CI: 2.37-5.89), Any therapy (OR: 3.93, 95%CI: 2.05-7.56), Polyp size ≥ 1 cm (OR: 4.14, 95%CI: 2.58-6.65), Endoscopy specialty: surgery or unknown (OR: 2.00, 95%CI: 1.30-3.08) | - |
Colonoscopy procedure includes treatment of foreign-body, submucosal injection, hemostasis, endoscopic ultrasound, transmural or intramural aspiration or biopsy.